CN1246865A - 具氟化17α－烷基链的抗孕激素活性类固醇 - Google Patents

具氟化17α－烷基链的抗孕激素活性类固醇 Download PDF

Info

Publication number
CN1246865A
CN1246865A CN98802361A CN98802361A CN1246865A CN 1246865 A CN1246865 A CN 1246865A CN 98802361 A CN98802361 A CN 98802361A CN 98802361 A CN98802361 A CN 98802361A CN 1246865 A CN1246865 A CN 1246865A
Authority
CN
China
Prior art keywords
pentafluoroethyl
hydroxy
group
dien
estr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98802361A
Other languages
English (en)
Chinese (zh)
Inventor
W·士威德
A·克利夫
U·克拉
G·尼夫
K·华立兹
M·士尼德
U·福门
H·荷布－史达普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of CN1246865A publication Critical patent/CN1246865A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN98802361A 1997-02-07 1998-02-09 具氟化17α－烷基链的抗孕激素活性类固醇 Pending CN1246865A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19706061.7 1997-02-07
DE19706061A DE19706061A1 (de) 1997-02-07 1997-02-07 Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB001290150A Division CN1202120C (zh) 1997-02-07 2000-09-25 具氟化17α－烷基链的抗孕激素活性类固醇

Publications (1)

Publication Number Publication Date
CN1246865A true CN1246865A (zh) 2000-03-08

Family

ID=7820508

Family Applications (2)

Application Number Title Priority Date Filing Date
CN98802361A Pending CN1246865A (zh) 1997-02-07 1998-02-09 具氟化17α－烷基链的抗孕激素活性类固醇
CNB001290150A Expired - Fee Related CN1202120C (zh) 1997-02-07 2000-09-25 具氟化17α－烷基链的抗孕激素活性类固醇

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB001290150A Expired - Fee Related CN1202120C (zh) 1997-02-07 2000-09-25 具氟化17α－烷基链的抗孕激素活性类固醇

Country Status (35)

Country Link
US (4) US6316432B1 (enExample)
EP (1) EP0970103B1 (enExample)
JP (1) JP4324249B2 (enExample)
KR (1) KR100511815B1 (enExample)
CN (2) CN1246865A (enExample)
AR (1) AR010887A1 (enExample)
AT (1) ATE216397T1 (enExample)
AU (1) AU742834B2 (enExample)
BG (1) BG63875B1 (enExample)
BR (1) BR9807667A (enExample)
CA (1) CA2280041C (enExample)
CL (1) CL2004001191A1 (enExample)
CZ (1) CZ296328B6 (enExample)
DE (2) DE19706061A1 (enExample)
DK (1) DK0970103T3 (enExample)
EA (1) EA003092B1 (enExample)
EE (1) EE03831B1 (enExample)
ES (1) ES2175673T3 (enExample)
HK (1) HK1040718B (enExample)
HU (1) HUP0000968A3 (enExample)
ID (1) ID22643A (enExample)
IL (1) IL131226A (enExample)
IS (1) IS2190B (enExample)
MY (1) MY118508A (enExample)
NO (1) NO313554B1 (enExample)
NZ (1) NZ336989A (enExample)
PL (1) PL191808B1 (enExample)
PT (1) PT970103E (enExample)
SI (1) SI0970103T1 (enExample)
SK (1) SK283155B6 (enExample)
TR (1) TR199901855T2 (enExample)
TW (1) TW499434B (enExample)
UA (1) UA66783C2 (enExample)
WO (1) WO1998034947A1 (enExample)
ZA (1) ZA98985B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311833C (zh) * 2000-10-18 2007-04-25 舍林股份公司 肿瘤细胞生长因子依赖性的抑制
CN101541823B (zh) * 2006-11-15 2012-10-03 拜耳先灵医药股份有限公司 孕酮受体拮抗剂

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
UY26965A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
HRP20030387A2 (en) * 2000-10-18 2005-04-30 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone dependent diseases
DE10051609A1 (de) * 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
JP2004511523A (ja) * 2000-10-18 2004-04-15 シエーリング　アクチエンゲゼルシャフト 細胞におけるアポトシスの誘発のための抗黄体ホルモンの使用
UY26966A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
CA2433776A1 (en) * 2001-01-09 2002-09-06 Schering Aktiengesellschaft The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20030013694A1 (en) * 2001-05-25 2003-01-16 Jens Hoffmann Use and compositions of antiprogestins for treatment of prostate diseases
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
JP2005536463A (ja) * 2002-05-03 2005-12-02 シエーリング アクチエンゲゼルシャフト １７α−フルオロアルキル−１１β−ベンズアルドキシムステロイド、それらの製造方法、これらのステロイド類を含有する製剤及び医薬品製造のためのそれらの使用
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
US7593347B2 (en) * 2003-12-29 2009-09-22 Intel Corporation Method and apparatus to exchange channel information
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
US9283234B2 (en) 2006-10-24 2016-03-15 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
WO2008128791A2 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
DE102009034367A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
SG183924A1 (en) 2010-03-22 2012-10-30 Repros Therapeutics Inc Compositions and methods for non-toxic delivery of antiprogestins
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US20160296534A1 (en) 2013-04-11 2016-10-13 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US9603856B2 (en) 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
EP2868321A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for inhibiting autocrine HCG production in adult human cells
MX2017014844A (es) 2015-05-18 2018-02-19 Bayer Pharma AG Regimen modulador selectivo de los receptores de progesterona (sprm).
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE310541C (enExample) * 1915-12-19 1919-01-30
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
US5064821A (en) * 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
JP2785023B2 (ja) * 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
JPH02188599A (ja) * 1988-11-16 1990-07-24 Roussel Uclaf ３―ケト―デルタ―４，９―１９―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
CN1055929C (zh) * 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311833C (zh) * 2000-10-18 2007-04-25 舍林股份公司 肿瘤细胞生长因子依赖性的抑制
CN101541823B (zh) * 2006-11-15 2012-10-03 拜耳先灵医药股份有限公司 孕酮受体拮抗剂

Also Published As

Publication number Publication date
SI0970103T1 (en) 2002-10-31
DE19706061A1 (de) 1998-08-13
EP0970103B1 (de) 2002-04-17
CA2280041C (en) 2007-10-23
IS2190B (is) 2007-01-15
SK283155B6 (sk) 2003-03-04
US20020045774A1 (en) 2002-04-18
HUP0000968A3 (en) 2001-03-28
JP4324249B2 (ja) 2009-09-02
US6503895B2 (en) 2003-01-07
CN1202120C (zh) 2005-05-18
MY118508A (en) 2004-11-30
EA003092B1 (ru) 2002-12-26
IL131226A0 (en) 2001-01-28
US20030134834A1 (en) 2003-07-17
CL2004001191A1 (es) 2005-03-28
US6316432B1 (en) 2001-11-13
CZ280599A3 (cs) 2000-01-12
ZA98985B (en) 1999-08-03
ES2175673T3 (es) 2002-11-16
JP2001510479A (ja) 2001-07-31
AR010887A1 (es) 2000-07-12
CA2280041A1 (en) 1998-08-13
US20050080060A1 (en) 2005-04-14
WO1998034947A1 (de) 1998-08-13
BR9807667A (pt) 2000-02-15
NZ336989A (en) 2001-04-27
NO993811D0 (no) 1999-08-06
HK1040718B (zh) 2005-12-09
ID22643A (id) 1999-12-02
TR199901855T2 (xx) 2000-04-21
CN1324802A (zh) 2001-12-05
KR100511815B1 (ko) 2005-09-05
NO313554B1 (no) 2002-10-21
EA199900644A1 (ru) 2000-04-24
IS5147A (is) 1999-08-04
PL191808B1 (pl) 2006-07-31
AU742834B2 (en) 2002-01-10
TW499434B (en) 2002-08-21
PT970103E (pt) 2002-09-30
ATE216397T1 (de) 2002-05-15
EE9900339A (et) 2000-02-15
BG103603A (en) 2000-06-30
HK1040718A1 (en) 2002-06-21
NO993811L (no) 1999-10-04
HUP0000968A2 (hu) 2000-10-28
US6806263B2 (en) 2004-10-19
AU6100598A (en) 1998-08-26
EE03831B1 (et) 2002-08-15
DK0970103T3 (da) 2002-07-22
CZ296328B6 (cs) 2006-02-15
US7148213B2 (en) 2006-12-12
UA66783C2 (en) 2004-06-15
EP0970103A1 (de) 2000-01-12
KR20000070835A (ko) 2000-11-25
SK103899A3 (en) 2000-05-16
BG63875B1 (bg) 2003-04-30
PL334878A1 (en) 2000-03-27
IL131226A (en) 2004-12-15
DE59803856D1 (de) 2002-05-23

Similar Documents

Publication Publication Date Title
CN1246865A (zh) 具氟化17α－烷基链的抗孕激素活性类固醇
FI85274C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 11 -(4-isopropenylfenyl) estra-4,9-diener.
CA2277924A1 (en) 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives
EP0847399A1 (en) Novel estrogens
JP5731498B2 (ja) １７−ヒドロキシ−１７−ペンタフルオロエチルエステル−４，９（１０）−ジエン１１−エチニルフェニル誘導体、その製造方法、及び疾病の治療のためのその使用
HUP9903353A2 (hu) 7Alfa-/5-metil-amino-pentil/-ösztratriének, e vegyületeket tartalmazó gyógyszerkészítmények és ezek alkalmazása gyógyszerek előállítására
CN1372565A (zh) 在11位带有烃取代基的非芳香族雌激素甾族化合物
JP3048637B2 (ja) Ｄ−ホモ−（１６−ＥＮ）−１１β−アリール４−エストレン、その製法並びに医薬としてのその使用
JP3302366B2 (ja) ゲスターゲン作用を有する１９，１１−架橋した４−エストレン
CN1220696C (zh) 16α－甲基或乙基取代的雌激素
MXPA99007057A (es) Esteroides con actividad antigestagena que tienen una cadena fluorada de 17-alfa-alquilo
CN1039328C (zh) D－高－(16－烯)－11β－芳基－4－雌烯－3－酮类化合物的制备方法
IE73240B1 (en) Steroids and therapeutic compositions containing same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication